cyrilzakka/clinical-trials huggingface dataset:
Ischemic Time and Extent of Myocardial Infarction (MI) With Cardiac Magnetic Resonance Imaging (CMRI) in Patients With ST Elevation Myocardial Infarction (STEMI) and Primary Percutaneous Coronary Intervention (PCI) Study

This study will assess relationship between ischemic time and the extent of myocardial infarction with cardiac magnetic resonance image in patients with STEMI (ST elevation myocardial infarction) and primary percutaneous coronary intervention.

Background:

Cardiac magnetic resonance image (CMRI) is the preferred method of assessing myocardial infarct size and function. However,the relationship between CMRI changes and the ischemic time \[symptom onset to device activation time (S2D)\] in patients with primary percutaneous coronary intervention (PCI) is not well understood.

Hypothesis:

The investigators will test the primary hypothesis that there is strong (at least 70%) direct correlation between the S2D time and infarct size by CMRI and inverse correlation with myocardial salvage.

Method:

The investigators will study a prospective cohort of 80 consecutive patients with STEMI and primary PCI. The investigators will perform CMRI at day 3 to 1 post STEMI and a repeat CMRI 30 to 40 days post STEMI.

Exclusion Criteria:

The investigators will exclude patients with 1)-culprit lesion in the distal artery, 2)-glomerular filtration rate (GFR) \< 60 mL/min/1.73m2, 3)-pacemaker, defibrillator, aneurysm clips, 4)-body weight \> 400lb, 5)-history of allergic reactions to gadlinium based contrast agents, and 6)-those unwilling to participate in the study protocol.

Outcome Measurement:

The primary outcome measure is the CMRI myocardial infarct size (scar). The secondary outcomes include the CMRI transmurality of scar, area at risk, myocardial salvage index, microvascular obstruction (MVO), left ventricle (LV) thrombus, and LV ejection fraction (EF). Important covariates include symptoms and ST segment resolution before and after the PCI, peak cardiac troponin (cTn), and angiographic TIMI flow and myocardial perfusion grade.

Follow-up:

Patients will be followed with repeat CMRI at 30 to 40 days and with phone survey at 6 months and 12 months.

Eligibility Criteria:
Inclusion Criteria:

Clinical features, EKG, cTn elevation, and coronary catheterization findings consistent with an acute STEMI and having primary PCI, with age greater than 18 years, and GFR \>= 60 mL/min/1.73m2.

Exclusion Criteria:

1. Renal dysfunction (creatinine clearance \< 60 mL/min/1.73m2)
2. Pregnancy or breast-feeding
3. Standard contra-indications to MRI for implanted ferro-magnetic devices - i.e.: pacemakers, defibrillator (AICD), and aneurysm clips
4. Body weight \> 400lb
5. Unwilling to participate in the research protocol
6. History of allergic reactions to gadlinium based contrast agents.
7. Too critically ill to receive a MRI
Risk Factors and Characteristics of COVID 19 Infection in Patients With Haematological Diseases

1. assessment of risk factor of covid 19 in haematological patients
2. assessment of characteristics of covid 19 in haematological patients

An ongoing outbreak of pneumonia associated with a novel coronavirus, severe acute respiratory syndrome (SARS) coronavirus 2, was reported in Wuhan, Hubei Province, China, in December 2019 .

In the following weeks, infections spread across China and other countries around the world .

The Chinese public health, clinical, and scientific communities took action to allow for timely recognition of the new virus and shared the viral gene sequence to the world .

On January 30, 2020, the World Health Organization (WHO) declared the outbreak a Public Health Emergency of International Concern

. On February 12, 2020, the WHO named the disease caused by the novel coronavirus "coronavirus disease 2019" (COVID-19) .

A group of international experts, with a range of specializations, have worked with Chinese counterparts to try to contain the outbreak .

Preliminary reports suggest that patients with an underlying malignancy have inferior outcomes.

While haematology patients are thought to be at increased risk of developing severe complications both due to immune dysfunction from their underlying haematological disorder and immunosuppressive therapies used for treatment, delays in treatment of the underling malignancy may compromise patient safety and survival. Data from other cohorts worldwide suggest mortality from COVID-19 is higher in haematology patients compared to the general population, with reported mortality rates between 39% and 50% in other British haematology patient cohorts.

In particular, a recent UK case series reported significantly higher case fatality rates in haematology patients receiving immunosuppressive or cytotoxic therapy within three months of COVID-19 diagnosis, raising concerns about the delivery of systemic anti-cancer therapy (SACT) during the pandemic.

There is an ongoing need to share collective experience regarding the clinical course of COVID-19 in patients with haematological disorders, particularly regarding implications for SACT delivery, in order to enable patients to receive treatment in a timely and safe manner during the pandemic.

Eligibility Criteria:
Inclusion Criteria:

* patients with haematological diseases who suspected or confirmed to COVID 19 infection..
* patients with age more than 18 years old

Exclusion Criteria:

* patients under the age of 18.
* Patients who refuse to contribute in this study.
Chongqing Diabetes Registry Study

To investigate the risk factors and biomarkers of the microvascular disease，macrovascular disease and neuropathy in patients with diabetes.

This study is a prospective cohort study. About 5000 patients with diabetes from the Chongqing Diabetes Centre,Chongqing,China, will be enrolled for long-term follow-up.Information on socio-demographic parameters, medical history, current drug use,lifestyle factors, anthropometric measurements, metabolic control indicators and diabetes complications examination will be documented. Blood and urine samples will be collected. This study aimed to assess risk factors and biomarkers of occurrence and development of diabetic microvascular disease,macrovascular disease and neuropathy in patients with diabetes.

Eligibility Criteria:
Inclusion Criteria:

1. Diagnosis of diabetes mellitus（based on the 1999 WHO diagnostic cretirial）;
2. Age younger than 75 years old, gender is not limited;
3. Voluntary to sign on the informed consent.

Exclusion Criteria:

1. pregnant or breast-feeding women;
2. Patients with chronic disease requiring long-term glucocorticoid therapy;
3. Patients with severe infection (except for diabetic foot) or immune dysfunction.
Effect of Infant Formula With Bovine Lactoferrin and Low Iron Concentration on Infant Health and Immune Function

Breast milk is the gold standard of early infant nutrition and breastfed infants have advantages in several short and long term outcomes compared to those formula-fed.

The first aim of this study is to evaluate the effect of adding bovine lactoferrin to infant formula. The general hypothesis is that bovine lactoferrin reduces some of the previously observed differences between formula-fed and breast-fed infants with regard to health and development. The main outcome studied is the effect on immune function. The second aim is to study the effects of lower iron concentration in infant formula and to test the hypothesis that iron can be lowered without negative effects on health and development. The main outcome studied here is iron status. Other outcomes in this trial are microbiota composition, metabolomics, growth, body composition and cognitive development.

To test the lactoferrin hypothesis, formula-fed infants will be recruited and fed a low iron (2 mg/L) control formula, or the same formula supplemented with bovine lactoferrin. To test the iron hypothesis, a third group will be fed the same formula (no lactoferrin) with higher iron concentration (8 mg/L). Group allocation for all formula-fed infants will be double-blind randomized. Additionally, breast-fed infants will be recruited and used as a reference group (gold standard).


Eligibility Criteria:
Inclusion Criteria:

Formula-fed healthy infants at 6 +/- 2 weeks of age with:

* birth weight 2500-4500 g
* gestational age at birth ≥ 37 completed weeks
* no chronic disease or neonatal diagnoses believed to affect any outcome
* no given blood transfusions or iron supplements

Exclusion Criteria:

-
Study of Evobrutinib in Participants With RMS (evolutionRMS 2)

The study is to evaluate the efficacy and safety of evobrutinib administered orally twice daily versus Teriflunomide (Aubagio®), administered orally once daily in participants with Relapsing Multiple Sclerosis (RMS). Participants who complete the double-blind treatment period (DBTP) and double-blind extension period (DBEP) prior to approval of a separate long-term follow-up study in their country will get an option for evobrutinib treatment continuation through a 96-week open-label extension (OLE) period.


Eligibility Criteria:
Inclusion Criteria:

* Participants are diagnosed with RMS (relapsing-remitting multiple sclerosis \[RRMS\] or secondary progressive multiple sclerosis \[SPMS\] with relapses) in accordance with 2017 Revised McDonald criteria (Thompson 2018)
* Participants with one or more documented relapses within the 2 years before Screening with either: a. one relapse which occurred within the last year prior to randomization, OR b. the presence of at least 1 gadolinium-enhancing (Gd+) T1 lesion within 6 months prior to randomization
* Participants have Expanded Disability Status Scale (EDSS) score of 0 to 5.5 at Screening and Baseline (Day 1). Participants with an EDSS score less than or equal to \[\<=\] 2 at Screening and Baseline (Day 1) are only eligible for participation if their disease duration (time since onset of symptoms) is no more than 10 years
* Participants are neurologically stable for \>= 30 days prior to both screening and baseline (Day 1)
* Female participants must be neither pregnant nor breast-feeding or must lack child-bearing potential (as defined by either: post-menopausal or surgically sterile), or use an effective method of contraception for the duration of the study and at least 2 years after study intervention due to the long elimination period for teriflunomide of 2 years, unless the participant undergoes an accelerated elimination procedure
* Male participants must refrain from donating sperm and/or abstain from intercourse with women of child-bearing potential or use an effective method of contraception for the duration of the study and at least 2 years after study intervention due to the long elimination period for teriflunomide of 2 years, unless the participant undergoes an accelerated elimination procedure
* Participants have given written informed consent prior to any study-related procedure
* Other protocol defined inclusion criteria could apply.

Exclusion Criteria:

* Participants diagnosed with Progressive MS, in accordance with the 2017 Revised McDonald criteria as follows: a). Participants with Primary Progressive MS. b) Participants with secondary progressive MS without evidence of relapse
* Disease duration more than (\>) 10 years in participants with an EDSS =\< 2.0 at screening and Baseline (Day 1)
* Immunologic disorder other than MS, or any other condition requiring oral, intravenous (IV), intramuscular, or intra-articular corticosteroid therapy, with the exception of well-controlled Type 2 diabetes mellitus or well controlled thyroid disease
* Other protocol defined exclusion criteria could apply.
Biomarkers for Muscle Function and Aging in Chronic HIV Infection

MATCH is an observation study of HIV-infected adults on effective antiretroviral therapy (ART) and demographically matched uninfected adults to evaluate muscle and aging.

MATCH is a non-randomized observational longitudinal study. We will recruit HIV infected adults (50 to 65 years old) and demographically matched uninfected control subjects to be followed for 4 years over the course of a 5 year study. The targeted age range of 50-65 is chosen to evaluate aging HIV infected individuals at risk for early frailty in the United States. All subjects will undergo blood draws and physical function assessment, and a subset will undergo a CT scan of muscle and will have a muscle biopsy taken.

A substudy will be performed on a subgroup of HIV-infected and HIV-uninfected men from the main cohort to measure daily physical activity by using an activity tracker.

Eligibility Criteria:
Inclusion Criteria:

Group 1: HIV positive subjects

* HIV positive
* English speaking
* 50-65 years old
* On Antiretroviral therapy and an HIV viral load below 200 copies/ml
* CD4 equal to or greater than 350 cells/mm3
* Postmenopausal (women)
* Lower extremity mobility sufficient to participate in functional assessment.

Group 2: HIV negative subjects Inclusion Criteria for Group 2 subjects

* English speaking
* 50-65 years old
* Negative for HIV (based on an HIV antibody test at Study Visit 1)
* Matched to Group 1 for sex (50% W, 50% M) and age (50 - 65yo)
* Postmenopausal (women)
* Lower extremity mobility sufficient to participate in functional assessment.

Exclusion Criteria:

Exclusion Criteria for Group 1 Subjects

* Acute or serious illness within 60 days prior to entry
* Use of pharmacologic doses of corticosteroids in the past 6 months.
* Use of anabolic therapy in the past 6 months.
* Lower extremity mobility insufficient to participate in functional assessment.
* Current use (last 30 days) of anticoagulants or known bleeding disorder.

Exclusion Criteria for Group 2 subjects

* Acute or serious illness within 60 days prior to entry
* Use of pharmacologic doses of corticosteroids in the past 6 months
* Use of anabolic therapy in the past 6 months
* Lower extremity mobility insufficient to participate in functional assessment
* Current use (last 30 days) of anticoagulants or known bleeding disorder.
High Intensity Interval Inspiratory Training Effect on Ventilatory Functions and Diaphragmatic Excursion in Forward Head Posture

PURPOSE: ......... The purpose of the study is to investigate the effect of interval inspiratory muscle training on respiratory functions in subjects with forward head posture associated with chronic nonspecific neck pain

BACKGROUND: Alteration of head and neck positions can have an immediate negative effect on respiratory function. Clinicians should be prompted to assess respiratory function when assessing individuals with FHP and decrease the tension on respiratory system to avoid consequence. Also FHP has a negative effect on chest expansion and diaphragmatic function

the incidence of forward head posture increases nowadays due to increase using of smartphones HYPOTHESES:: There will be no a significant effect of interval inspiratory muscle training on respiratory functions in chronic forward head posture subjects.

RESEARCH QUESTION: Will the interval inspiratory muscle training improve respiratory functions in subjects forward head posture associated with chronic nonspecific neck pain?

* For evaluation: we will assess 1-diaphragmatic excursion using ultrasonography 2- ventilatory functions using spirometer 3- chest expansion using tape measurement 4- height and weight scale to detect BMI 5- Craniocervical angle
* For treatment: we will use 1- threshold inspiratory muscle trainer

And they will be randomly allocated into two groups:

Experimental Group: Thirty subjects will receive combined program containing interval inspiratory muscle training and conventional exercise program for FHP 12 weeks (3 sessions/ week)

Control Group : Twenty subjects will receive conventional exercise program for FHP 12 weeks (3 sessions/ week)

Eligibility Criteria:
Inclusion Criteria:

* Sixty subjects (female) have forward heads and Their craniocervical angle is from 30 to 50°
* Their body mass index ranged from (24.9 -29.9) kg/m2

Exclusion Criteria:

* Chest diseases (either obstructive or restrictive).
* Smoker patient.
* Clinical signs of a severe cardiac event. (eg, congestive heart failure),
* Neurological disorders affecting respiratory muscles or any muscular dystrophies (cervical disc or bulge).
* Patient with haemodynamic instability.
Amotivational Syndrome and Fatigue in Neurosurgery

Depression is a major public concern associated with profound distress, intense suffering, and impairment in social, professional and familial functioning. Among the numerous symptoms defining depression, fatigue and motivation are not only frequent but also highly associated with poor quality of life and resistance to conventional antidepressant. Recent data, mainly obtained in animals, suggest that these symptoms may be linked to inflammatory processes within the central nervous system. Yet access to the brain is too invasive for exploring this link in patients with psychiatric conditions. However, certain conditions in neurosurgery, such as aneurysm rupture, require external evacuation, over several days or weeks, of the fluid bathing the brain through a catheter directly inserted into it. Critically, these patients also exhibit extreme exhaustion and fluctuating motivation, allowing to investigate the involvement of neuroinflammation in lack of motivation and fatigue by carrying out repeated motivation assessments with short behavioral tests (around ten minutes), while performing an analysis of inflammation markers in the fluid evacuated from the brain. The identification of inflammatory mechanisms underlying lack of motivation and fatigue could lead to the development of treatments for both resistant depression and motivation deficits that largely hamper rehabilitation in neurosurgery.


Eligibility Criteria:
Inclusion Criteria:

* Age \>= 18 years old
* Patients required an external cerebrospinal fluid drainage

Exclusion Criteria:

* Pregnant or breast feeding patient
* Patient under legal protection
* Patient opposition to participate in this study
Mills Manipulation and Mulligan PRP Affect Pain, Grip Strength and Function on Lateral Epicondylitis

The aim of this study is to find the comparative effects of mills manipulation with or without Mulligan pain release phenomena on the pain, grip strength, and function in patients with Lateral Epicondylitis. The results of this study will provide clinicians with valuable insights into the most effective treatment approach for lateral epicondylitis, enabling them to stay up-to-date with the latest practice methods and optimize patient care.


Eligibility Criteria:
Inclusion Criteria:

* Subjects diagnosed with lateral epicondylitis with positive Cozen test
* NPRS \>3
* Both male and female patients
* Sub-acute lateral epicondylitis \>4weeks-\<3 months
* Subjects with age range 20-40 year

Exclusion Criteria:

* Acute lateral epicondylitis
* Subjects with elbow and around elbow fracture
* Subjects with ligament injury around elbow joint
* Any neurological conditions
* Any open wounds around the area of elbow
* Hyper-sensitive skin, skin allergies, diagnosed subjects with malignancy, diagnosed subjects skin diseases, diagnosed subjects with systemic illness
* Traumatic injury to the elbow joint
A Study of LY2969822 in Healthy Participants

The purpose of this study is to evaluate how safe LY2969822 (study drug) is and whether it causes any side effects. The study will also measure how much of the study drug gets into the blood stream and how long it takes the body to get rid of the study drug. This is the first time that this study drug is being given to participants. This study is for research purposes only and is not intended to treat any medical condition.

Participants in Part A will complete three study periods, which together will last about 40 days. Participants in Parts B and C will complete one study period which will last about 17 days, but the total study time is about 40 days. Each participant may only enroll in one part. Screening is required within 28 days prior to the start of the study for all participants.

Eligibility Criteria:
Inclusion Criteria:

* Male participants must agree to use a reliable method of birth control in addition to having their partner use another method for the duration of the study and for 3 months after the last dose of LY2969822
* Female participants must not be of child-bearing potential
* Participants have a body mass index (BMI) of 18.5 to 29.9 kilogram per meter square (kg/m\^2), inclusive, at screening

Exclusion Criteria:

* Have participated, within the last 30 days (prior to first dose in this study), in a clinical trial involving an investigational product
* Have a significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal (GI), endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data
* Intended use of over-the-counter medication within 14 days prior to dosing or during the study with the exception of vitamins and mineral supplements or occasional paracetamol or acetaminophen
* Intended use of herbal supplements or prescription medications, other than stable doses of thyroid or estrogen hormone replacement, within 14 days prior to dosing or during the study
M-learning to Improve Professional Competencies in Health Sciences

The aim of this study is to investigate whether a mobile application is useful for improving knowledge about professional competencies in students enrolled in Health Sciences degrees.

The learning environment in Higher Education as well as autonomous work of students, mobile technology is increasingly present due to the mass use of mobile devices and the development of high speed in data transmission, which provides today the possibility of being able to access in real time a great amount of information.

M-learning is defined as the ability to access educational resources, tools and materials using a mobile device anytime and anywhere.

Considering the advantages of this technology, m-learning can be a real option to the traditional teaching-learning method by encouraging the active participation of students in their own learning process.

Therefore, this educational innovation study aims to evaluate the effectiveness and the use of a mobile application as a complementary learning strategy in interactive format for the acquisition of professional competencies in Health Sciences.

Eligibility Criteria:
Inclusion Criteria:

* Signed informed consent
* Access last generation mobile phone
* Enroll 1º course Health Sciences degrees
* Basic english knowledge

Exclusion Criteria:

* Prior experience in Fundaments subject (second enrolment or more not allowed)